Design Therapeutics (DSGN) to Release Quarterly Earnings on Wednesday

Design Therapeutics (NASDAQ:DSGN) is anticipated to issue its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:30 AM ET.

Design Therapeutics (NASDAQ:DSGN) last issued its quarterly earnings data on Tuesday, April 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.07. On average, analysts expect Design Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Design Therapeutics Stock Performance

Shares of DSGN opened at $13.30 on Monday. The stock has a 50 day simple moving average of $11.40 and a 200 day simple moving average of $9.72. Design Therapeutics has a 52-week low of $3.11 and a 52-week high of $17.25. The firm has a market capitalization of $830.72 million, a PE ratio of -11.08 and a beta of 1.73.

Institutional Investors Weigh In On Design Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in shares of Design Therapeutics during the 4th quarter worth approximately $212,000. AlphaCentric Advisors LLC bought a new stake in shares of Design Therapeutics during the 4th quarter worth approximately $190,000. JPMorgan Chase & Co. raised its stake in shares of Design Therapeutics by 26.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 23,221 shares of the company’s stock worth $175,000 after purchasing an additional 4,896 shares in the last quarter. Deutsche Bank AG bought a new stake in shares of Design Therapeutics during the 4th quarter worth approximately $146,000. Finally, MetLife Investment Management LLC raised its stake in shares of Design Therapeutics by 47.8% during the 4th quarter. MetLife Investment Management LLC now owns 15,249 shares of the company’s stock worth $143,000 after purchasing an additional 4,929 shares in the last quarter. Institutional investors own 56.64% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on DSGN. Oppenheimer began coverage on Design Therapeutics in a research report on Wednesday, January 7th. They set an “outperform” rating and a $18.00 price target for the company. Wall Street Zen downgraded Design Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 price target on shares of Design Therapeutics in a research report on Wednesday. Royal Bank Of Canada upped their price target on Design Therapeutics from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Finally, Jefferies Financial Group began coverage on Design Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $15.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.